# Richard A. Morgan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/richard-a-morgan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,590 |
| Field | CAR-T cell therapy research |
| h-index | 51 |
| i10-index | 87 |
| Last Known Institution | Biogen (United States) |
| OpenAlex ID | https://openalex.org/A5103198733 |
| ORCID iD | https://orcid.org/0000-0003-0689-0916 |
| Works | 225 |

## Researcher papers

- [Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1](https://scholariq.org/papers/tumor-regression-in-patients-with-metastatic-synovial-cell-sarcoma-and-melanoma/)
- [A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response](https://scholariq.org/papers/a-pilot-trial-using-lymphocytes-genetically-engineered-with-an-ny-eso-1-reactive/)
- [Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma](https://scholariq.org/papers/pilot-trial-of-adoptive-transfer-of-chimeric-antigen-receptor-transduced-t-cells/)

## Researcher topics

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Virus-based gene therapy research](https://scholariq.org/topics/virus-based-gene-therapy-research-2/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [CRISPR and Genetic Engineering](https://scholariq.org/topics/crispr-and-genetic-engineering/)
- [RNA Interference and Gene Delivery](https://scholariq.org/topics/rna-interference-and-gene-delivery/)

## Researcher university

- [Biogen (United States)](https://scholariq.org/institutions/biogen-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.